Last reviewed · How we verify
NCT06610149: IBS-dammil5
A Novel Probiotic Mixture in Adults With IBS
NA trial testing Probiotic mixture in Irritable Bowel Syndrome in 1,098 participants. Completed in 31 August 2023.
30 June 2023
Quick facts
| Lead sponsor | University of Bari |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,098 |
| Start date | 1 October 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Probiotic mixture — full drug profile →
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Sponsor
University of Bari
Who can join
Adults 18 to 99, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Irritable bowel syndrome (IBS) is faced by gastroenterologists on a daily basis and probiotics are a potential therapeutic tool, however, there is no strain recommendations. This multicenter re-al-world, single-arm, open-label study aims to assess the effectiveness, safety, and patient satis-faction of a novel probiotic mixture in patients with IBS. Methods: This study is conducted by Italian gastroenterologists who enroll patients with IBS. Throughout the 8-week treatment (T1) period with a probiotic mixture (Lactobacillus paracasei 101/37 LMG P-17504, Lac-tobacillus plantarum 14D CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500, and Bifidobacterium animalis ssp. lactis Bi1 LMG P-17502), participants complete a questionnaire to evaluate IBS symptoms at baseline, at the end of treatment, and after one-month follow-up (T2).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults.
Drago L, Corleto VD, Ciprandi G, Brindicci VF, et al · · 2025 · PMID 40987448 · DOI 10.1163/18762891-bja00097
Verify or expand the search:
- PubMed search for NCT06610149
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic mixture
Trials testing the same drug.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT05815511 — Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Rosacea Evolution · NA · completed
- NCT05498948 — PMS Promotes the Recovery of Patients After Heart Valve Replacement · NA · completed
- NCT05599607 — Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Areata · NA · completed
- NCT04145713 — Effects of Probiotic Mixture Supplementation and Evaluation of Intestinal Mucosal Tolerance and Gut Microbiome in Newbor · Phase 3 · unknown
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other University of Bari trials
Trials by the same sponsor.
- NCT06854133 — Factors of Effectiveness in Italian Forensic Treatment · not yet recruiting
- NCT07125625 — Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome · NA · not yet recruiting
- NCT07036627 — Intestinal Microbiota After PPI Treatment · not yet recruiting
- NCT07050693 — Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections. · NA · recruiting
- NCT06719999 — PRIMA Project- Box for Heath and Tradition (B4HT) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06610149 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bari
- Last refreshed: 24 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06610149.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing